Abstract | OBJECTIVE: DESIGN: Current PI documents for donepezil, galantamine, rivastigmine, and memantine were obtained from American manufacturers' websites, accessed in September, 2007. Adverse events (AEs) data for each drug versus placebo were compiled and analyzed using odds ratios. RESULTS: CONCLUSIONS: Data from this review suggest that gastrointestinal side effects are typical of ChEIs. Problems with rivastigmine tolerability may be reduced by transdermal administration. Memantine provides a distinctive tolerability profile. It is important to note that this study sought to overcome the lack of direct-comparison trials by analyzing the data presented by each company in its own PI material; however, caution should be exercised when comparing values obtained from different trials or trial groups.
|
Authors | Gustavo Alva, Jeffrey L Cummings |
Journal | Psychiatry (Edgmont (Pa. : Township))
(Psychiatry (Edgmont))
Vol. 5
Issue 11
Pg. 27-36
(Nov 2008)
ISSN: 1550-5952 [Print] United States |
PMID | 19724715
(Publication Type: Journal Article)
|